In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.

Janssen is looking for a 2021 approval in patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.